Should I buy or sell Spero Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRO shares. View SPRO analyst ratings or view top-rated stocks .

What is Spero Therapeutics' stock price target for 2024?

2 Wall Street analysts have issued 12 month price targets for Spero Therapeutics' shares. Their SPRO share price targets range from $7.00 to $7.00. On average, they expect the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 451.2% from the stock's current price. View analysts price targets for SPRO or view top-rated stocks among Wall Street analysts .

How have SPRO shares performed in 2023?

Spero Therapeutics' stock was trading at $1.73 at the beginning of 2023. Since then, SPRO stock has decreased by 26.6% and is now trading at $1.27. View the best growth stocks for 2023 here .

When is Spero Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our SPRO earnings forecast .

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics, Inc. (NASDAQ:SPRO) released its earnings results on Monday, November, 13th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.17. The company earned $25.47 million during the quarter, compared to analysts' expectations of $2.40 million. Spero Therapeutics had a positive trailing twelve-month return on equity of 4.14% and a negative net margin of 2.08%.

What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO?

27 employees have rated Spero Therapeutics Chief Executive Officer Ankit Mahadevia, MD on Glassdoor.com . Ankit Mahadevia, MD has an approval rating of 100% among the company's employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE) , Matinas BioPharma (MTNB) , ADMA Biologics (ADMA) , Editas Medicine (EDIT) , SCYNEXIS (SCYX) , Kadmon (KDMN) , Aldeyra Therapeutics (ALDX) , KushCo (KSHB) , Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN) .

When did Spero Therapeutics IPO?

(SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Who are Spero Therapeutics' major shareholders?

Spero Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include AWM Investment Company Inc. (0.63%), Acadian Asset Management LLC (0.52%), Group One Trading L.P. (0.00%), Rock Springs Capital Management LP (0.11%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ankit Mahadevia , Aquilo Capital Management, Llc, Cristina Larkin, Kamal Hamed, Sath Shukla and Timothy Keutzer. View institutional ownership trends .

How do I buy shares of Spero Therapeutics?

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Spero Therapeutics Stock Price, News & Analysis (NASDAQ:SPRO)

$1.27

-0.02 (-1.55%)

(As of 12/6/2023 ET)

Compare

Today's Range: $1.21
▼
$1.31
50-Day Range: $1.00
▼
$1.29
52-Week Range: $0.99
▼
$2.04

Volume: 155,056 shs
Average Volume: 357,771 shs
Market Capitalization: $67.31 million

P/E Ratio: 127.00
Dividend Yield: N/A
Price Target: $7.00

Spero Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 451.2% Upside
$7.00 Price Target
Short Interest: Healthy
2.13% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.80
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$50,160 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.50) to ($0.60) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

256th out of 957 stocks

Biotechnology Industry

12th out of 67 stocks

3.5

Analyst's Opinion

Consensus Rating
Spero Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, Spero Therapeutics has a forecasted upside of 451.2% from its current price of $1.27.
Amount of Analyst Coverage
Spero Therapeutics has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.13% of the outstanding shares of Spero Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Spero Therapeutics has a short interest ratio ("days to cover") of 4.7.
Change versus previous month
Short interest in Spero Therapeutics has recently decreased by 10.32%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Spero Therapeutics does not currently pay a dividend.
Dividend Growth
Spero Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Spero Therapeutics has received a 74.17% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Spero Therapeutics is -0.80.

0.6

News and Social Media Coverage

Search Interest
5 people have searched for SPRO on MarketBeat in the last 30 days.
MarketBeat Follows
Only 2 people have added Spero Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Spero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $50,160.00 in company stock.
Percentage Held by Insiders
Only 4.21% of the stock of Spero Therapeutics is held by insiders.
Percentage Held by Institutions
Only 27.25% of the stock of Spero Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Spero Therapeutics are expected to decrease in the coming year, from ($0.50) to ($0.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Spero Therapeutics is 127.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 116.44.
Price to Earnings Ratio vs. Sector
The P/E ratio of Spero Therapeutics is 127.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 106.64.
Price to Book Value per Share Ratio
Spero Therapeutics has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Spero Therapeutics Stock (NASDAQ:SPRO)

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

SPRO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SPRO Stock News Headlines

November 28, 2023 | americanbankingnews.com

Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below Two Hundred Day Moving Average of $1.39

November 14, 2023 | finance.yahoo.com

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2023 Earnings Call Transcript

December 7, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 14, 2023 | finanznachrichten.de

Spero Therapeutics, Inc.: Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update

November 13, 2023 | benzinga.com

Recap: Spero Therapeutics Q3 Earnings

November 13, 2023 | finance.yahoo.com

Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update

November 12, 2023 | msn.com

Spero Therapeutics Q3 2023 Earnings Preview

November 12, 2023 | markets.businessinsider.com

Here's what Wall Street expects from Spero Therapeutics's earnings report

December 7, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

November 6, 2023 | finance.yahoo.com

Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

November 2, 2023 | businesswire.com

SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

November 1, 2023 | finance.yahoo.com

Spero Therapeutics to Present at Upcoming November Investor Conferences

November 1, 2023 | finanznachrichten.de

Spero Therapeutics, Inc.: Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

October 18, 2023 | finance.yahoo.com

All You Need to Know About Spero Therapeutics, Inc. (SPRO) Rating Upgrade to Buy

September 20, 2023 | finance.yahoo.com

Spero Therapeutics to Present at Cantor’s Global Healthcare 2023 Investor Conference

September 16, 2023 | finance.yahoo.com

Insider Sell: Chief Medical Officer Kamal Hamed Sells 39,496 Shares of Spero Therapeutics Inc

September 6, 2023 | finance.yahoo.com

Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

September 5, 2023 | markets.businessinsider.com

4 Analysts Have This to Say About Spero Therapeutics

August 31, 2023 | msn.com

Spero Therapeutics (SPRO) Price Target Increased by 5.26% to 6.80

August 29, 2023 | finance.yahoo.com

Spero Therapeutics, Inc. (SPRO) Upgraded to Strong Buy: What Does It Mean for the Stock?

August 22, 2023 | finance.yahoo.com

Down -11.72% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround

August 16, 2023 | nasdaq.com

Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%

August 14, 2023 | msn.com

HC Wainwright & Co. Maintains Spero Therapeutics (SPRO) Buy Recommendation

August 14, 2023 | markets.businessinsider.com

HC Wainwright & Co. Maintains Buy Rating for Spero Therapeutics: Here's What You Need To Know

August 13, 2023 | finance.yahoo.com

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2023 Earnings Call Transcript

August 11, 2023 | finance.yahoo.com

Q2 2023 Spero Therapeutics Inc Earnings Call

August 10, 2023 | finance.yahoo.com

Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update

See More Headlines

Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 12/07/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SPRO
CUSIP: N/A
CIK: 1701108
Web: sperotherapeutics.com
Phone: (857) 242-1600
Fax: N/A
Employees: 35
Year Founded: 2013

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $7.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +451.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.01
Trailing P/E Ratio: 127.00
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-46,420,000.00
Net Margins: -2.08%
Pretax Margin: 0.77%
Return on Equity: 4.14%
Return on Assets: 2.33%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.01
Quick Ratio: 4.01

Sales & Book Value

Annual Sales: $53.51 million
Price / Sales: 1.26
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.45 per share
Price / Book: 0.88

Miscellaneous

Outstanding Shares: 53,000,000
Free Float: 50,768,000
Market Cap: $67.31 million
Optionable: Optionable
Beta: 0.86

Social Links

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Ankit Mahadevia M.D. (Age 42)
MBA, Co-Founder & Chairman of the Board
Comp: $1.24M
Mr. Satyavrat Shukla C.F.A. (Age 51)
President, CEO & Director
Comp: $823.27k
Ms. Tamara Lynn Joseph L.L.M. (Age 60)
Chief Legal Officer
Comp: $775.55k
Ms. Esther P. Rajavelu (Age 44)
CFO & Chief Business Officer
Mr. Timothy Keutzer (Age 55)
Chief Operating Officer
Ted Jenkins
VP & Head of Investor Relations
Mr. James P. Brady
Chief Human Resource Officer
Dr. Kamal Hamed M.B.A. (Age 62)
M.D., M.P.H., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SPRO Stock Analysis - Frequently Asked Questions

Should I buy or sell Spero Therapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRO shares.
View SPRO analyst ratings or view top-rated stocks.
What is Spero Therapeutics' stock price target for 2024?: 2 Wall Street analysts have issued 12 month price targets for Spero Therapeutics' shares. Their SPRO share price targets range from $7.00 to $7.00. On average, they expect the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 451.2% from the stock's current price.
View analysts price targets for SPRO or view top-rated stocks among Wall Street analysts.
How have SPRO shares performed in 2023?: Spero Therapeutics' stock was trading at $1.73 at the beginning of 2023. Since then, SPRO stock has decreased by 26.6% and is now trading at $1.27.
View the best growth stocks for 2023 here.
When is Spero Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our SPRO earnings forecast.
How were Spero Therapeutics' earnings last quarter?: Spero Therapeutics, Inc. (NASDAQ:SPRO) released its earnings results on Monday, November, 13th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.17. The company earned $25.47 million during the quarter, compared to analysts' expectations of $2.40 million. Spero Therapeutics had a positive trailing twelve-month return on equity of 4.14% and a negative net margin of 2.08%.
What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO?: 27 employees have rated Spero Therapeutics Chief Executive Officer Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among the company's employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spero Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Kadmon (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).
When did Spero Therapeutics IPO?: (SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.
Who are Spero Therapeutics' major shareholders?: Spero Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include AWM Investment Company Inc. (0.63%), Acadian Asset Management LLC (0.52%), Group One Trading L.P. (0.00%), Rock Springs Capital Management LP (0.11%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ankit Mahadevia, Aquilo Capital Management, Llc, Cristina Larkin, Kamal Hamed, Sath Shukla and Timothy Keutzer.
View institutional ownership trends.
How do I buy shares of Spero Therapeutics?: Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SPRO) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial